Questcor Pharmaceuticals — Investor Presentation (October 2011)
29 slides from Questcor Pharmaceuticals's investor presentation, Oct 28, 2011
Slide 1: Questcor Pharmaceuticals October 2011
NASDAQ: QCOR Exhibit 99.1 NASDAQ: QCOR October 2011
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa
Slide 3: Questcor: A biopharmaceutical company for difficult-to-treat conditions
Questcor A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions 3 A biopharmaceutical company whose product helps patients with serious, difficult-to-treat medical conditions
Slide 4: Questcor Overview
Questcor Overview Flagship Product: • Profitable, cash flow positive, $180M* in cash, debt-free • 19 approved indications Key Markets: • Multiple Sclerosis, Nephrotic Syndrome, Infantile Spasms • Combined market opportunity exceeds $1.5 billion Strategy: • Grow Acthar sales in each key market • Deve
Slide 5: History of Acthar
History of Acthar 1950 2000 2010 5 1952 First Approved 1950 1978 MS Indication Added 2000 2001 Questcor Acquires Acthar 2010 Label Modernized 19 Indications 2007 Questcor Changes Strategy 2010
Slide 6: Significant Barriers to Entry
Significant Barriers to Entry 6
Slide 7: QCOR Strategy – Sell More Acthar
QCOR Strategy – Sell More Acthar 7 Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Systemic Lupus Erythematosus Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS)
Slide 8: Acthar and MS
8 Acthar and MS Inadequate Response to Steroids Poor Venous Access Problematic Steroid Side Effects Acthar when “Steroids are not suitable” *Based on prescriptions written 8 Neurodegenerative disorder Acute treatment for relapses Treatment for 1-2 weeks* $40K-$50K/Rx Inadequate Response to Steroids
Slide 9: MS Script - Record of Consistent Growth
9 MS Script - Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which
Slide 10: Monthly MS Scripts Have 160% CAGR
Monthly MS Scripts Have 160% CAGR 10 15-30 reps 30-38 reps 38-77 reps
Slide 11: MS Trends
11 • Doubled sales force: 38 to 77 sales reps Nov 2010 • Q3-2011 results – Q3-11 new, paid Rxs up 174% vs. Q3-10 – MS about 65% of QCOR net sales* • Estimated $150M annualized run-rate* – About 450 prescribers in Q3 – September was a record month MS Trends Doubled sales force: 38 to 77 sales reps No
Slide 12: Acthar and Nephrotic Syndrome (NS)
12 • Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Significant unmet need – Few treatment options • Treatment for 4-6 months* • $150K-250K/Rx Acthar and Nephrotic Syndrome (NS) *Base
Slide 13: NS Scripts – Off to a Good Start
13 NS Scripts – Off to a Good Start New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the
Slide 14: Estimated total: 20,000-25,000 patients
Estimated total: 20,000-25,000 patients ( QUESTCOR’
Slide 15: NS Sales Trends
15 • Hired 5 reps to sell Acthar to nephrologists – Initiated sales efforts in early March 2011 – Q1 2011 new, paid NS Rxs: 18 – Q2 2011 new, paid NS Rxs: 45 – Q3 2011 new, paid NS Rxs: 60 • Expanded NS selling effort: 5 to 28 NS during Q3 • Planned sales calls to increase in Q4 by 7X over Q2 • 6 mo
Slide 16: NS Phase IV Company Sponsored Study
16 • Treatment Resistant Idiopathic Membranous Nephropathy • Dose response trial – Randomized, double blinded 3 arm study with 2 different dosage regimens of Acthar and placebo – n=84 (approximate), 35 centers (approximate) – Endpoint is reduction of proteinuria • Trial milestones – “First look” dat
Slide 17: Infantile Spasms
17 • Devastating, refractory form of childhood epilepsy – Very poor developmental outcome if inadequately treated • Not responsive to standard anti-epileptic drugs • Ultra-rare orphan disorder – 1,500 to 2,000 patients annually • Typically occurs in children less than 2 years old • Characterized by
Slide 18: Acthar and IS
18 • Standard of care for years, FDA approval 10/15/10 • Crisis therapy • Treatment for 2-4 weeks* • In a randomized, single-blinded, controlled study, 87% of patients achieved overall response (no spasms and no hypsarrhythmia) at two weeks versus 29% on prednisone • $100K-$125K/Rx – About half of p
Slide 19: IS Sales Trends
19 • Targeting select institutions – Promotion effort being narrowed as market is maturing – Creates selling time for Acthar MS reps to target NS • Significant variability in quarterly Rxs • Q3-2011 new, paid Rxs within historic range – Acthar currently used to treat 40-50% of IS patients IS Sales T
Slide 20: Total Acthar Sales Force
20 • Specialty Sales Force – Main focus on MS (time split is ~ 80%/15%/5% on MS/NS/IS) – 77 representatives, 13 regional managers, one national director • Nephrology Sales Force – Focus 100% on Nephrotic Syndrome – 28 representatives, 4 regional managers, one national director – Full force commenced
Slide 21: Immediate Acthar Growth Opportunities
21 Immediate Acthar Growth Opportunities *Represents estimated net sales market opportunity based on internal company estimates MS NS IS Build on sales momentum, good market headroom Market size $500M+* Significantly expanded selling effort to 28 reps during Q3 Market size $1B+* Targeted sales strat
Slide 22: Systemic Lupus Erythematosus (Lupus)
22 • High unmet need • Serious health risk if unsuccessfully treated • Difficult to treat • Multiple on-label indications for Acthar – Exacerbations – Maintenance therapy – Lupus nephritis • Large patient population Systemic Lupus Erythematosus (Lupus) High unmet need Serious health risk if unsucces
Slide 23: Financials
23 Financials Profitable Debt Free Cash Flow Positive Profitable Debt Free Cash Flow Positive
Slide 24: Q3-2011 Financial Results
24 Net Sales ($M) Gross Margin Operating Income ($M) Fully Diluted, GAAP EPS $ 59.8 94% $33.6 $0.35 $31.3 93% $16.8 $0.18 Q3-2011 Q3-2010 Record Net Sales (up 91%) and Solid Earnings (EPS up 94%) Q3-2011 Financial Results Net Sales ($M) Gross Margin Operating Income ($M) Fully Diluted, GAAP EPS $ 59
Slide 25: Debt-free balance sheet
Cash / ST Investments Accounts Receivable $180M* $24M 10/21/11 25 Debt-free balance sheet Questcor is Cash Flow Positive *After return of $78 million of cash to shareholders through share repurchases. Cash / ST Investments Accounts Receivable $180M* $24M 10/21/11 Debt-free balance sheet
Slide 26: Share Repurchases
26 Share Repurchases: 15 Million Shares • 2.2 Million Preferred shares repurchased • 13.2 Common shares repurchased • $78 million returned to shareholders in stock buybacks • 62.7 million shares currently outstanding • 4.3 million shares remain on buyback authorization Repurchases significantly impr
Slide 27: Go Forward Plan - Sell More Acthar
27 • Sustain effort and momentum with MS • Execute with expanded NS selling effort • Maintain and gradually grow IS sales • Explore Systemic Lupus Erythematosus (Lupus) as another vertical market • Develop other markets for Acthar – Acthar is its own pipeline with many other on-label and many possib
Slide 28: Investment Highlights
28 Investment Highlights High margins provide good operating leverage Announced new vertical market -- Lupus Sales in MS and NS are growing rapidly, yet market penetration is low Acthar is approved for 19 indications-many in large markets with sizable unmet need Acthar has sustainable competitive ad
Slide 29: October 2011
NASDAQ: QCOR October 2011 NASDAQ: QCOR October 2011
Questcor Pharmaceuticals — Investor Presentation (October 2011) on 6ix